The effect of alendronate administration on bone mineral density alone and combined with continuous combined oral estradiol and norethisterone in postmenopausal women
Küçük Resim Yok
Tarih
2000
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Tek başına ya da sürekli kombine hormon replasman tedavisi ile birlikte alendronat uygulanmasının postmenapozal kadınlardaki kemik mineral yoğunluğuna etkisinin araştırılması. Menapoz kliniğimize başvuran kemik mineral yoğunluk skoru düşük (T-skor < -1) 54 postmenopozal kadın çalışmaya alındı. Hastalar randomize olarak 2 gruba ayrıldı. Birinci grupda 21 tane postmenapozal yalnızca alendronate ve kalsiyum kullanan hasta yer aldı. İkinci grupta 23 hastaya 2 mg 17-beta estradiol ve 1 mg noretisteron, alendronate ve kalsiyum ile birlikte uygulandı. Tedavi öncesi ve bir yıl sonra DXA yöntemiyle lumbal ve proksimal femur kemik dansitometresi ölçümleri yapıldı. Lumbar ve femur trokanter ortalama kemik dansite ölçümleri, alendrofiate/kalsiyum ve alendronate/kalsiyum ile birlikte kombine estrojen ve progesteron kullanan her iki grupta da tedavi sonrasında anlamlı ölçüde arttı (P<0.01). İki grup kemik mineral dansitesi artışı açısından karşılaştırıldığında aralarında anlamlı farklılık saptanmadı (P>0.05). Tek başına ya da sürekli kombine estrojen ve progestogen ile birlikte alendronat uygulanmasının postmenapozal osteopenik kadınlarda kemik mineral dansitesi üzerinde olumlu etkisi vardır. Fakat iki tedavi grubu karşılaştırıldığında aralarında anlamlı fark bulunmamaktadır.
OBJECTIVE: To evaluate the efficacy of alendronate administration on bone mineral density used alone or combined with oral continuous combined hormone replacement therapy in postmenopausal women. STUDY DESIGN: 54 postmenopausa! women who had low scores (T-scores <-1) in bone mineral density were included into the study. the patients were randomized in two groups. First group consisted of 31 women who were steered to use only alendronate and calcium. Second group included 23 women and treated -with a combined estrogen and progestogen (2 mg 17-beta estradiol and 1 mg norethisterone) besides alendronate and calcium. Before and one year after the commencement of treatment, bone mineral density of lumbar spine, proximal femur were measured by DXA densitometers. RESULTS: the mean lumbar and femur trochanter bone mineral density values were found to be significantly increased after the treatment in both alendronate/calcium and alendronate/calcium and combined estrogen and progestogen groups (P<0.01). There was no significant difference when both groups were compared with respect to increase in bone mineral density (P>0.05). CONCLUSION: Our findings suggest that both alendronate administration used alone or combined with continuous combined estrogen and progesterone has beneficial effects on bone mineral density in postmenopausal osteopenic women; however there was no significant difference when both treatment groups were compared.
OBJECTIVE: To evaluate the efficacy of alendronate administration on bone mineral density used alone or combined with oral continuous combined hormone replacement therapy in postmenopausal women. STUDY DESIGN: 54 postmenopausa! women who had low scores (T-scores <-1) in bone mineral density were included into the study. the patients were randomized in two groups. First group consisted of 31 women who were steered to use only alendronate and calcium. Second group included 23 women and treated -with a combined estrogen and progestogen (2 mg 17-beta estradiol and 1 mg norethisterone) besides alendronate and calcium. Before and one year after the commencement of treatment, bone mineral density of lumbar spine, proximal femur were measured by DXA densitometers. RESULTS: the mean lumbar and femur trochanter bone mineral density values were found to be significantly increased after the treatment in both alendronate/calcium and alendronate/calcium and combined estrogen and progestogen groups (P<0.01). There was no significant difference when both groups were compared with respect to increase in bone mineral density (P>0.05). CONCLUSION: Our findings suggest that both alendronate administration used alone or combined with continuous combined estrogen and progesterone has beneficial effects on bone mineral density in postmenopausal osteopenic women; however there was no significant difference when both treatment groups were compared.
Açıklama
Anahtar Kelimeler
Kadın Hastalıkları ve Doğum
Kaynak
GORM:Gynecology Obstetrics & Reproductive Medicine
WoS Q Değeri
Scopus Q Değeri
Cilt
6
Sayı
1
